Amano USA Holdings acquires Accu-Time Systems

NewsGuard 100/100 Score

Today Amano USA Holdings, Inc. (AUH) announces the acquisition of Accu-Time Systems, Inc. (ATS) based in Ellington, CT.  "Amano and ATS share a common vision and the combination of our products and people provides an enhanced value proposition to our customers," said Michael Lee, CEO of AUH.

ATS is a leading developer, manufacturer, and supplier of biometric and non-biometric terminals to the Time and Attendance and Workforce Management industry in the USA and more recently into Europe and other export markets. The company has a strong reputation and tradition of innovative and reliable hardware solutions for its growing customer base of business partners. "We look forward to continuing and expanding the ATS tradition of providing quality innovative products here and abroad," said Michael Lee. "The acquisition just made too much sense as ATS brings products and innovation that will leverage Amano's extensive offerings while Amano adds significant breadth and innovation to ATS," said Peter DiMaria, President and Founder of ATS.

The acquisition of ATS will provide a good synergistic effect to Amano's sales channels for time and workforce management. We can also look forward to continuing growth in our businesses by leveraging the innovation that ATS brings to Amano.

In joining the Amano Group of companies, ATS will gain greater access to overseas markets and benefit from the global engineering and support infrastructure that Amano can provide. ATS's valued business partners will share in these benefits of greater market coverage as well as technical resources of a larger group.

ATS will continue to be lead by Mr. DiMaria and his management team, "Having been in our industry 20 years we have always been aware of Amano as a quality supplier of time and attendance products. We have admired their dedication to quality and consistency from afar.  Once we started talking among ourselves the agreement became a compelling opportunity for both of us," said Mr. DiMaria.

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment